Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis

J Dermatolog Treat. 2020 Dec;31(8):763-768. doi: 10.1080/09546634.2019.1640348. Epub 2019 Jul 22.

Abstract

Background: Tildrakizumab is a high-affinity, humanized, IgG1 κ, anti-interleukin-23 monoclonal antibody approved for moderate-to-severe plaque psoriasis.Objectives: This analysis examined whether tildrakizumab's week-28 efficacy can be sustained or improved to week 52.Methods: Psoriasis patients on the same-dose tildrakizumab (100 or 200 mg) in the first 52 weeks achieving week-28 PASI ≥50 were pooled from two phase-3 randomized controlled trials, and grouped into four mutually exclusive week-28 PASI response groups. Patients' week-52 PASI responses were compared to their week-28 PASI responses.Results: Of 352 patients receiving 100-mg tildrakizumab, 10.5%, 25.3%, 38.4%, and 25.9% achieved PASI 50-74, 75-89, 90-99, and 100 at week 28, respectively. Among patients achieving PASI ≥90, ≥75, or ≥50 at week 28, 89.4%, 91.1%, or 97.4% maintained their week-28 PASI responses at week 52, respectively. Among patients achieving PASI 50-74, 75-89, or 90-99 at week 28, 64.8%, 33.7%, or 25.2% improved their week-28 PASI responses at week 52, respectively.Limitations: This post hoc analysis may be less robust than an a priori analysis.Conclusions: Most tildrakizumab-treated patients with week-28 PASI ≥75 maintained their week-28 PASI improvement at week 52. More than half of week-28 partial responders (PASI 50-74) improved their PASI responses to PASI ≥75 at week 52. Clinicaltrials.gov identifiers: NCT01722331, NCT01729754.

Keywords: PASI; Tildrakizumab; psoriasis; sustained efficacy.

Publication types

  • Clinical Trial, Phase III
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Etanercept / therapeutic use
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Interleukin-23 / antagonists & inhibitors*
  • Male
  • Middle Aged
  • Psoriasis / drug therapy*
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunosuppressive Agents
  • Interleukin-23
  • tildrakizumab
  • Etanercept

Associated data

  • ClinicalTrials.gov/NCT01722331
  • ClinicalTrials.gov/NCT01729754